SNSE News and Press, Sensei Biotherapeutics Inc. From 02/28/24

- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade - - Topline efficacy and biomarker data for both monotherapy and combination arms of dose escal...

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will present at the following confe...

- Completed SNS-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities - - Expands patient cohort in specific tumor types - - Multiple clinical milestones expected in 2024 - - Strong balance sheet with cash runway extended into the fourth quart...

Sensei Biotherapeutics Inc. (SNSE) is expected to report $-0.28 for Q3 2023

2023-11-07 08:29:18 ET More on Sensei Biotherapeutics Seeking Alpha’s Quant Rating on Sensei Biotherapeutics Historical earnings data for Sensei Biotherapeutics Financial information for Sensei Biotherapeutics For further details see: Sensei Biothe...

- SNS-101 initial Phase 1 clinical data presented at SITC demonstrate potential best-in-class safety and pharmacokinetic profile, with no cytokine release syndrome or dose-limiting toxicities reported - - Phase 1/2 trial of SNS-101 continues to enroll ahead of schedule, with new...

2023-11-06 10:03:02 ET DENVER, Colo., Nov. 6, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; OrganiGram Holdings Inc (NASDAQ: OGI), British American Tobacco PLC (NYSE: BTI), Sensei Biotherapeutics Inc (N...

2023-11-06 09:32:11 ET DENVER, Colo., Nov 6, 2023 ( www.247marketnews.com )- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) presented, after Friday’s market close, initial monotherapy dose-escalation portion data from its Phase 1/2 clinical trial for SNS-101, a conditionally active,...

- Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encouraging cytokine release profile across multiple dose cohorts - - First VISTA-blocking antibody administered at a dose anticipated to be therap...

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the appointment of Stephanie Krebs, MS, MBA, as Chief Busin...